{"id":3567,"date":"2026-07-30T07:44:03","date_gmt":"2026-07-30T07:44:03","guid":{"rendered":"https:\/\/pharmaaffinity.com\/amarsayaracademy\/?p=3567"},"modified":"2026-07-30T13:12:33","modified_gmt":"2026-07-30T13:12:33","slug":"big-breaking-new-scheme-by-pci","status":"publish","type":"post","link":"https:\/\/pharmaaffinity.com\/amarsayaracademy\/pharma\/government\/big-breaking-new-scheme-by-pci\/","title":{"rendered":"PCI Carryover Scheme 2026 for Existing B.Pharm Students"},"content":{"rendered":"\n<p class=\"wp-block-paragraph\">The <strong>Pharmacy Council of India (PCI)<\/strong> has officially announced a <strong>Carryover Provision<\/strong> for existing <strong>B.Pharm students admitted up to the academic year 2025\u20132026<\/strong>. This decision aims to ensure that students admitted under the previous B.Pharm syllabus are not academically disadvantaged during the transition to the revised <strong>B.Pharm Syllabus (2026)<\/strong> based on the <strong>National Education Policy (NEP) 2020<\/strong>.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">The notification was issued through <strong>Reference No. 14-154\/2025-PCI<\/strong> following the decision taken in <strong>Item No. 15 of the 447th Executive Committee (EC) meeting held on 2 July 2026<\/strong>.<\/p>\n\n\n\n<hr class=\"wp-block-separator has-alpha-channel-opacity\"\/>\n\n\n\n<h1 class=\"wp-block-heading\">Why Did PCI Introduce the Carryover Scheme?<\/h1>\n\n\n\n<p class=\"wp-block-paragraph\">Beginning with the <strong>2026\u20132027 academic session<\/strong>, PCI has implemented a <strong>new B.Pharm syllabus based on NEP 2020<\/strong>. Students admitted from 2026\u201327 onward will study under this revised curriculum.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">However, students admitted <strong>up to the academic year 2025\u20132026<\/strong> will continue under the syllabus and regulations that were applicable at the time of their admission. The carryover provision has been introduced to help these students complete their degree without being forced to shift to the new curriculum.<\/p>\n\n\n\n<hr class=\"wp-block-separator has-alpha-channel-opacity\"\/>\n\n\n\n<h1 class=\"wp-block-heading\">Who Is Eligible?<\/h1>\n\n\n\n<p class=\"wp-block-paragraph\">The carryover provision applies only to:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li>Students admitted to <strong>B.Pharm up to the academic year 2025\u20132026<\/strong><\/li>\n\n\n\n<li>Students studying under the <strong>B.Pharm Syllabus (2016\u20132017)<\/strong><\/li>\n\n\n\n<li>Students who have backlog subjects but wish to continue their studies<\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\">Students admitted from <strong>2026\u20132027 onwards<\/strong> will study exclusively under the <strong>new B.Pharm Syllabus (2026)<\/strong>.<\/p>\n\n\n\n<hr class=\"wp-block-separator has-alpha-channel-opacity\"\/>\n\n\n\n<h1 class=\"wp-block-heading\">Key Features of the PCI Carryover Provision<\/h1>\n\n\n\n<p class=\"wp-block-paragraph\">According to the official notification:<\/p>\n\n\n\n<h3 class=\"wp-block-heading\">Students can continue to the next semester<\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">Eligible students will be permitted to progress to the <strong>next higher semester<\/strong> even if they have backlog courses.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\">Attendance is allowed<\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">Students may attend regular classes of the next semester irrespective of pending backlog subjects.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\">Backlogs can be carried forward<\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">Instead of repeating an entire academic year, students may carry forward their backlog courses while continuing with higher semesters.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\">Applicable up to the Eighth Semester<\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">Students can continue in this manner until the completion of the <strong>Eighth Semester<\/strong>.<\/p>\n\n\n\n<hr class=\"wp-block-separator has-alpha-channel-opacity\"\/>\n\n\n\n<h1 class=\"wp-block-heading\">Attendance Relaxation<\/h1>\n\n\n\n<p class=\"wp-block-paragraph\">Since admissions under the <strong>2016\u20132017 syllabus<\/strong> will stop after the implementation of the new syllabus, PCI has also permitted institutions to help students meet attendance requirements through:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li>Special classes<\/li>\n\n\n\n<li>Additional instructional hours<\/li>\n\n\n\n<li>Classes beyond regular timings<\/li>\n\n\n\n<li>Study leave periods<\/li>\n\n\n\n<li>Other arrangements approved by the institution<\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\">These measures are intended to help students satisfy the minimum attendance requirement and complete the programme successfully.<\/p>\n\n\n\n<hr class=\"wp-block-separator has-alpha-channel-opacity\"\/>\n\n\n\n<h1 class=\"wp-block-heading\">Important Points Students Should Know<\/h1>\n\n\n\n<ul class=\"wp-block-list\">\n<li>The carryover provision is <strong>only for existing B.Pharm students<\/strong> admitted up to <strong>2025\u20132026<\/strong>.<\/li>\n\n\n\n<li>Students will continue under the <strong>old B.Pharm regulations (2016\u20132017 syllabus)<\/strong>.<\/li>\n\n\n\n<li>New admissions from <strong>2026\u20132027<\/strong> will follow the <strong>revised B.Pharm Syllabus (2026)<\/strong>.<\/li>\n\n\n\n<li>Universities and institutions are responsible for ensuring students complete the programme according to the applicable regulations.<\/li>\n<\/ul>\n\n\n\n<hr class=\"wp-block-separator has-alpha-channel-opacity\"\/>\n\n\n\n<h1 class=\"wp-block-heading\">Benefits of the New Carryover Scheme<\/h1>\n\n\n\n<ul class=\"wp-block-list\">\n<li>No unnecessary loss of an academic year<\/li>\n\n\n\n<li>Better academic continuity<\/li>\n\n\n\n<li>Opportunity to clear backlog subjects while studying<\/li>\n\n\n\n<li>Reduced stress for students<\/li>\n\n\n\n<li>Easier transition to the new education framework<\/li>\n\n\n\n<li>Improved chances of completing the degree within the prescribed period<\/li>\n<\/ul>\n\n\n\n<hr class=\"wp-block-separator has-alpha-channel-opacity\"\/>\n\n\n\n<h1 class=\"wp-block-heading\">Does This Apply to D.Pharm Students?<\/h1>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>No.<\/strong><\/p>\n\n\n\n<p class=\"wp-block-paragraph\">The official notification uploaded here is <strong>specifically issued for existing B.Pharm students admitted up to the academic year 2025\u20132026<\/strong>. It does <strong>not mention D.Pharm students or ER-2020 regulations<\/strong>. Therefore, D.Pharm students should not assume that this carryover provision automatically applies to them unless PCI issues a separate notification.<\/p>\n\n\n\n<hr class=\"wp-block-separator has-alpha-channel-opacity\"\/>\n\n\n\n<h1 class=\"wp-block-heading\">Final Words<\/h1>\n\n\n\n<p class=\"wp-block-paragraph\">The PCI Carryover Provision is a significant relief for existing <strong>B.Pharm students<\/strong> studying under the 2016\u20132017 syllabus. By allowing eligible students to progress to higher semesters while carrying backlog subjects, PCI aims to ensure a smoother transition to the new NEP-based curriculum without disrupting the education of currently enrolled students.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Students are advised to stay in touch with their college or university and follow official PCI notifications for any further implementation guidelines.<\/p>\n\n\n\n<hr class=\"wp-block-separator has-alpha-channel-opacity\"\/>\n\n\n\n<h2 class=\"wp-block-heading\">FAQs<\/h2>\n\n\n\n<h3 class=\"wp-block-heading\">Is the PCI carryover scheme applicable to all B.Pharm students?<\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">No. It applies only to students admitted <strong>up to the academic year 2025\u20132026<\/strong>.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\">Can students attend the next semester with backlogs?<\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">Yes. Eligible students may attend the next semester while carrying backlog subjects.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\">Will students be shifted to the new NEP syllabus?<\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">No. Existing students will continue under the syllabus and regulations under which they were originally admitted.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\">Does this notification apply to D.Pharm ER-2020 students?<\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">No. The uploaded notification is only for <strong>existing B.Pharm students<\/strong> and does not extend the provision to D.Pharm students.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><\/p>\n\n\n\n<figure class=\"wp-block-embed is-type-video is-provider-youtube wp-block-embed-youtube wp-embed-aspect-16-9 wp-has-aspect-ratio\"><div class=\"wp-block-embed__wrapper\">\n<iframe loading=\"lazy\" title=\"\ud83d\udea8 PCI New Notice 2026 | Ab Back Ki Tension Khatam? \ud83d\ude31 Complete Update | B.Pharmacy Latest News\" width=\"820\" height=\"461\" src=\"https:\/\/www.youtube.com\/embed\/cTsrkA0L9cs?feature=oembed\" frameborder=\"0\" allow=\"accelerometer; autoplay; clipboard-write; encrypted-media; gyroscope; picture-in-picture; web-share\" referrerpolicy=\"strict-origin-when-cross-origin\" allowfullscreen><\/iframe>\n<\/div><\/figure>\n<!-- AddThis Advanced Settings generic via filter on the_content --><!-- AddThis Share Buttons generic via filter on the_content -->","protected":false},"excerpt":{"rendered":"<p>The Pharmacy Council of India (PCI) has officially announced a Carryover Provision for existing B.Pharm students admitted up to the academic year 2025\u20132026. This decision aims to ensure that students admitted under the previous B.Pharm syllabus are not academically disadvantaged during the transition to the revised B.Pharm Syllabus (2026) based on the National Education Policy [&hellip;]<!-- AddThis Advanced Settings generic via filter on get_the_excerpt --><!-- AddThis Share Buttons generic via filter on get_the_excerpt --><\/p>\n","protected":false},"author":1,"featured_media":3571,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"om_disable_all_campaigns":false,"_monsterinsights_skip_tracking":false,"_monsterinsights_sitenote_active":false,"_monsterinsights_sitenote_note":"","_monsterinsights_sitenote_category":0,"footnotes":""},"categories":[1],"tags":[],"class_list":["post-3567","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-government"],"aioseo_notices":[],"_links":{"self":[{"href":"https:\/\/pharmaaffinity.com\/amarsayaracademy\/wp-json\/wp\/v2\/posts\/3567","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pharmaaffinity.com\/amarsayaracademy\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pharmaaffinity.com\/amarsayaracademy\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pharmaaffinity.com\/amarsayaracademy\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/pharmaaffinity.com\/amarsayaracademy\/wp-json\/wp\/v2\/comments?post=3567"}],"version-history":[{"count":2,"href":"https:\/\/pharmaaffinity.com\/amarsayaracademy\/wp-json\/wp\/v2\/posts\/3567\/revisions"}],"predecessor-version":[{"id":3572,"href":"https:\/\/pharmaaffinity.com\/amarsayaracademy\/wp-json\/wp\/v2\/posts\/3567\/revisions\/3572"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/pharmaaffinity.com\/amarsayaracademy\/wp-json\/wp\/v2\/media\/3571"}],"wp:attachment":[{"href":"https:\/\/pharmaaffinity.com\/amarsayaracademy\/wp-json\/wp\/v2\/media?parent=3567"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pharmaaffinity.com\/amarsayaracademy\/wp-json\/wp\/v2\/categories?post=3567"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pharmaaffinity.com\/amarsayaracademy\/wp-json\/wp\/v2\/tags?post=3567"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}